Shares of Piramal Pharma jumped over 4% in Thursday's trade after the company announced the successful closure of a US Food and Drug Administration inspection at its manufacturing facility in Sellersville, Pennsylvania. According to Business Standard, the stock surged as much as 4.6% to touch an intraday high of ₹175.95, while trading at ₹172.35 as of 12:30 PM, up over 2.5% from the previous day's close of ₹168.10. In an exchange filing dated July 9, 2026, Piramal Pharma confirmed that the US FDA has issued an Establishment Inspection Report (EIR) for the Sellersville facility, marking the successful closure of the inspection process. The stock has significantly outperformed the broader markets in 2026, with the pharma counter gaining a meager 1.2% while the Nifty50 has tumbled 7.95% during the same period.
The successful closure of the inspection represents a significant regulatory milestone for Piramal Pharma. As reported by Business Standard, the issuance of the EIR indicates that the inspection process has been concluded, removing a key regulatory overhang for the pharmaceutical company. The inspection was conducted as a Good Manufacturing Practices (GMP) inspection between May 4-8, 2026 at the Sellersville facility. Initially, the regulator issued a Form-483 stating three observations, but at the closing meeting, these observations were classified as Voluntary Action Indicated (VAI), indicating no severe issues were found at the facility and no observation related to data integrity. The company prepared a detailed response to the observations, reiterating its commitments to maintaining high compliance standards and agreed to work closely with the authority to make all necessary changes.
Domestic brokerage firm JM Financial has retained its 'Buy' rating on Piramal Pharma with a target price of ₹218, implying an upside of 29% from the previous close of ₹168.11. According to Business Standard, the brokerage expects the company to outperform within the Contract Development and Manufacturing Organizations (CDMO) segment in the June quarter, with margins expanding by up to 200 basis points year-on-year. JM Financial projects Piramal Pharma's revenue to be ₹2,130 crore for the first quarter of FY27, while EBITDA could come in at ₹160 crore, representing a 50% year-on-year growth. The quarter is expected to be strong primarily due to the impact of key product destocking completed and new projects in existing folio.
As reported by PL Capital to Moneycontrol, the launch of generic semaglutide following the March 2026 patent expiry is expected to further support domestic growth and will be a key monitorable over the coming quarters. The brokerage expects favorable EBITDA growth for Lupin, Torrent Pharmaceuticals and Divi's Laboratories, while IPCA Laboratories and Ajanta Pharma are also likely to post healthy earnings. However, margin pressure is expected to persist for Dr Reddy's Laboratories, Cipla, Zydus Lifesciences and Anthem Biosciences, driven by a high US base and unfavorable product mix.
In addition to the regulatory closure announcement, Piramal Pharma informed about the upcoming annual general meeting scheduled on Thursday, July 30, 2026. As reported by NDTV Profit, the company's shares have been in the green since the beginning of 2026 with marginal gains of around 1.4%, while the pharma sector index Nifty Pharma gained 13.6% during the same period. However, the stock has been down by 14.68% over a year, when Nifty Pharma rose by 15.8%. Piramal Pharma operates in three major segments: Contract Development and Manufacturing Organizations (CDMO); Complex hospital generics (critical care); and Piramal Consumer Healthcare (PCH), as part of the Piramal group of companies.
